{"pub": "marketwatch", "url": "https://marketwatch.com/story/ucb-to-acquire-ra-pharmaceuticals-in-21-billion-deal-2019-10-10-21032845", "downloaded_at": "2019-10-10 06:55:41.184712+00:00", "title": "UCB to acquire Ra Pharmaceuticals in $2.1 billion deal", "language": "en", "text": "UCB S.A. will acquire U.S.-based Ra Pharmaceuticals Inc. for $2.1 billion in an all cash deal.\n\nShareholders of Ra Pharma RARX, +0.33% will receive $48 for each share held, a joint statement by the two companies said Thursday.\n\nThe transaction has been unanimously approved by the boards the two companies, the statement said, adding the deal is expected to be completed in the first quarter next year after regulatory approvals.\n\nUCB UCB, -0.25% will finance the acquisition via a combination of cash and loans.\n\nBank of America Merrill Lynch and Lazard were the financial advisors to UCB, while Ra Pharma was advised by Centerview Partners.\n\nRa Pharma is a biopharmaceutical company focused on rare diseases. Belgium-based UCB is also a biopharmaceutical company that focuses on severe diseases of the immune system or of the central nervous system.", "description": "Shareholders of Ra Pharma\u00a0will receive $48 for each share held, a joint statement by the two companies said Thursday.", "authors": [], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-10"}